The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma

Scientific Reports

Volumn 4, Issue , 2014, Pages 1-6

  Zhang, Yang ^a,b   Li, Jing ^a,b   Wang, Rui ^a,b   Li, Yuan ^a,b   Pan, Yunjian ^a,b   Cai, Deng ^a,b   Hu, Haichuan ^a,b   Li, Hang ^a,b   Ye, Ting ^a,b   Luo, Xiaoyang ^a,b   Zhang, Yiliang ^a,b   Li, Bin ^a,b   Shen, Lei ^a,b   Sun, Yihua ^a,b   Chen, Haiquan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NEUROFIBROMIN; PROTEIN KINASE INHIBITOR;

ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RISK; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROFIBROMIN 1; ODDS RATIO; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84946920704     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07163     Document Type: Article

References (20)

1. Travis, W. D. et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6, 244-285 (2011).
2. Hung, J. J. et al. Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival. J Clin Oncol (2014).
3. Campos-Parra, A. D. et al. Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. Eur Respir J 5, 1439-1447 (2014).
4. Yoshizawa, A. et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 8, 52-61 (2013).
5. Russell, P. A. et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol 8, 461-468 (2013).
6. Hung, J. J. et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg 258, 1079-1086 (2013).
7. Warth, A. et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30, 1438-1446 (2012).
8. Yoshizawa, A. et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24, 653-664 (2011).
9. Zhang, Y. et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 18, 1947-1953 (2012).
10. Cha, M. J. et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg 147, 921-928 e922 (2014).
11. Xu, L., Tavora, F. & Burke, A. Histologic features associated with metastatic potential in invasive adenocarcinomas of the lung. Am J Surg Pathol 37, 1100-1108 (2013).
12. Russell, P. A. et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 6, 1496-1504 (2011).
13. Sakurai, H. et al. Differences in the prognosis of resected lung adenocarcinoma according to the histological subtype: a retrospective analysis of Japanese lung cancer registry data. Eur J Cardiothorac Surg 45, 100-107 (2014).
14. Yoshida, T. et al. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol 139, 1691-1700 (2013).
15. Woo, T. et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int 62, 785-791 (2012).
16. de Bruin, E. C. et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 4, 606-619 (2014).
17. Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
18. Detterbeck, F. C., Boffa, D. J. & Tanoue, L. T. The new lung cancer staging system. Chest 136, 260-271 (2009).
19. Pan, Y. et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer 2, 121-126 (2014).
20. Wang, R. et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30, 4352-4359 (2012).